NEW YORK (GenomeWeb) – Roche's Ventana Medical Systems said that its Ventana System for Primary Diagnosis has received CE marking in the European Union for routine pathology, including primary diagnosis with human tissue specimens. The system comprises the Ventana Virtuoso software combined with either the Ventana iScan Coreo or the Ventana iScan HT slide scanner for the automated creation of digital slides, as well as automated case management and computer viewing of human tissue specimens. The iScan Coreo slide scanner is a brightfield 160-slide capacity scanner.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.